Fast Five Quiz: HR-Positive/HER2-Negative Breast Cancer

Winston W. Tan, MD

Disclosures

September 14, 2021

Preferred first-line systemic endocrine-based therapy options, which are category 1 recommendations (based on phase 3 clinical trial evidence) per National Comprehensive Cancer Network (NCCN) guidelines, include an aromatase inhibitor (anastrozole, exemestane, or letrozole) in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (palbociclib, ribociclib, or abemaciclib); fulvestrant with or without a nonsteroidal aromatase inhibitor (ie, anastrozole or letrozole); or fulvestrant in combination with a CDK4/6 inhibitor.

Given that patients with HR+/HER2- metastatic breast cancer will ultimately have disease progression after first-line therapy, second-line systemic endocrine-based therapy options must be considered. Preferred second-line systemic endocrine-based therapy options, which are category 1 recommendations per NCCN guidelines, include fulvestrant in combination with a CDK4/6 inhibitor (if a CDK4/6 inhibitor was not utilized in the first-line setting) or fulvestrant in combination with alpelisib (only in patients with PIK3CA mutations). Other preferred second-line systemic endocrine-based therapy options include everolimus in combination with exemestane, tamoxifen, or fulvestrant; fulvestrant monotherapy; nonsteroidal aromatase inhibitor monotherapy; or selective estrogen receptor modulator monotherapy.

A HER2-receptor antagonist, with or without chemotherapy, is used only for HER2+ breast cancer. Most women with HER2+ breast cancer will receive one or more chemotherapy drugs plus trastuzumab, the anti–HER2-receptor antagonist. Many studies have shown that these treatments dramatically improve survival for women with HER2+ breast cancer (SEER).

Learn more about medications for metastatic breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....